SANKOUL, South Korea, Nov. 20, 2023 /PRNewswire/ -- DeepBio announced today that it has been awarded the CES Innovation Award for being the first Korean company to use Artificial Intelligence for cancer diagnosis. A large electronics event, CES 2024, will be held in Las Vegas, USA, in the upcoming January, and it will be the world's largest electronics event.
Today, the Consumer Technology Association (CTA) announced the winners of CES Innovation Awards. During the Innovation Award category, DeepBio won for the first time in its history, when the A.I. diagnostic-aid software company was able to detect meaningful findings among cancer patients for the first time.
There is no doubt that DeepBio recognizes this award as a major achievement that demonstrates its world-class technology in cancer diagnosis and prognosis, as well as raising the profile of Korean cancer diagnosis Machine Learning firms.
With its expertise in deep learning and cancer pathology, DeepBio provides state-of-the-art in vitro diagnostic software (IVDs, SaMDs) that analyzes cancerous areas and severity to assist medical professionals in making better decisions about their patients' health. As a result, DeepBio's DeepDx®-Prostate offers an extremely high degree of precision, with a 99% sensitivity and 97% specificity.
As a result of DeepBio's technical excellence, it has been recognized both internally and externally, as it won the silver medal at the Edison Awards in the United States, commonly referred to as the "Oscar of Innovation" in 2021, which was won by Elon Musk of Tesla and Steve Jobs of Apple, as well as the first place award in the Chameleon Challenge, an event that evaluates image recognition software," said Kim Sun-woo, CEO of DeepBio.. As part of our mission, we will strive to improve the environment for cancer diagnosis and provide cutting-edge cancer diagnosis.. Through generous investments in technology, we are able to provide solutions to the biggest challenge of humanity, cancer, for medical professionals.
Through generous investments in technology, we are able to provide solutions to the biggest challenge of humanity, cancer, for medical professionals.
In the meantime, CES 2024 is scheduled to take place at the Las Vegas Convention Center in the United States from January 9th to 12th, and DeepBio's award can be found on the website of the CES Innovation Awards.
DeepBio: What it is and how it works
In the field of cancer pathology, DeepBio is a leading AI healthcare company that specializes in deep learning to advance the field. In order to provide pathologists and medical professionals with state-of-the-art diagnostic aids to enhance the accuracy of cancer diagnoses and prognoses, DeepBio has developed cutting-edge in vitro diagnostic software (IVD SaMD).. The company's main products include DeepDx® Prostate, a software that uses artificial intelligence for analyzing prostate cancer, which was the first in vitro diagnostic product in Korea to be approved by the Ministry of Food and Drug Safety.. A Silver Award was given to the product at the U.S. Consumer Electronics Show in 2019. In addition, the company won first place at the Chameleon Challenger, a global AI digital pathology image analysis competition, and was also named as one of the winners of the Medicine Awards, the Oscars of Innovation, which were won by Apple (2012) and Tesla (2014). DeepBio has been recognized as one of the top 100 AI startups in Korea for the third time in a row, and has been recognized as a company that will lead the innovation of digital healthcare in the future for the third year in a row. Please visit DeepBio's website at https://www.deepbio.com for more information about the company.Detailed biographical information.The company.The Korean krona
The Korean krona
Please contact Daeyeon Kim Manager (Diane Kim) at [email protected] or by calling the number below: 010-2938-6161
BIOGRAPHY OF THE SOURCE
A leading AI healthcare company, Deep Bio, a leading AI healthcare company specializing in deep learning and cancer pathology, is proud to announce its participation as an exhibitor in the 2018...
As a leader in the use of Artificial Intelligence (AI) in cancer diagnostics, Deep Bio announced today that it has been named to the Korea AI Startup 100 list.
Join PRN's weekly newsletter to receive PRN's top stories and curated news delivered straight to your inbox each week!

Source prnewswire